highest dose of glp 1 🚨 FDA just approved Foundayo™ (orforglipron) — Lilly's once-daily oral GLP- for obesity. The headline: 12.4% average body weight reduction at the over 72 weeks in ATTAIN-1. That's −27 lbs Zepbound Dosing: Doctor's Guide for

These are harder endpoints to achieve but more clinically meaningful

For some individuals, that balance can be appealing

However, despite these advances, there is still plenty of room and necessity for improvement

Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency

Over 68 weeks, with a starting dose of 2 mg escalated every 4 weeks: 9 mg dose: 26.4% average body weight reduction (29.1 kg / 64.2 lbs) 12 mg dose: 28.7% average body weight reduction (32.3 kg / 71.2 lbs) Placebo: 2.1% average body weight reduction The milestone achievements tell an even more compelling story

doi: 10.4239/wjd.v12.i7.1042 2 GaberySSalinasCGPaulsenSJAhnfelt-RnneJAlanentaloTBaqueroAFet al